HbA_1c Change and Diabetic Retinopathy During GLP-1 Receptor Agonist Cardiovascular Outcome Trials: A Meta-analysis and Meta-regression.

ABSTRACT:

Background

Long-term glycemic control reduces retinopathy risk, but transient worsening can occur with glucose control intensification. Glucagon-like peptide 1 receptor agonists (GLP-1RA) lower glucose, but the long-term impact on retinopathy is unknown. GLP-1RA cardiovascular outcome trials (CVOTs) provide long-term follow-up, allowing examination of retinopathy outcomes.

Purpose

To examine the associations between retinopathy, HbA_1c, systolic blood pressure (SBP), and weight in GLP-1RA CVOTs.

Data sources

Systematic review identified six placebo-controlled GLP-1RA CVOTs reporting prespecified retinopathy outcomes.

Study selection

Published trial reports were used as the primary data sources.

Data extraction

HbA_1c, SBP, and weight

SUBMITTER: Bethel MA 

PROVIDER: S-EPMC7783944 | biostudies-literature | 2021 Jan

REPOSITORIES: biostudies-literature